<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03551821</url>
  </required_header>
  <id_info>
    <org_study_id>ATI-50002-AAB-201</org_study_id>
    <nct_id>NCT03551821</nct_id>
  </id_info>
  <brief_title>Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata</brief_title>
  <official_title>An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Eyebrow Loss Due to Alopecia Areata, Alopecia Universalis or Alopecia Totalis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aclaris Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aclaris Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess the safety, tolerability and efficacy of&#xD;
      ATI-50002 Topical Solution in subjects with unilateral or bilateral loss of eyebrow hair due&#xD;
      to alopecia areata (AA), alopecia universalis (AU) or alopecia totalis (AT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label study which will be conducted at 1 to 2 sites.&#xD;
&#xD;
      Subjects will be required to have a clinical diagnosis of AA, AU or AT with unilateral or&#xD;
      bilateral loss of eyebrow hair.&#xD;
&#xD;
      Subjects will apply study medication to the entire affected eyebrow(s), twice-daily for 24&#xD;
      weeks.&#xD;
&#xD;
      Safety and tolerability will be evaluated throughout the study.&#xD;
&#xD;
      The duration of the study participation is anticipated to be a maximum of 233 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 11, 2018</start_date>
  <completion_date type="Actual">November 6, 2018</completion_date>
  <primary_completion_date type="Actual">November 6, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician's Eyebrow Assessment</measure>
    <time_frame>Six months</time_frame>
    <description>Determination of the amount of hair in the affected area.&#xD;
Clinician's Eyebrow Assessment&#xD;
Grade Descriptor 0 No eyebrow hair: No terminal hairs are visible in the affected area(s)&#xD;
A little eyebrow hair: Occasional terminal hairs are visible in the affected area(s)&#xD;
Some eyebrow hair: Numerous terminal hairs are visible in the affected area(s)&#xD;
Most eyebrow hair: Mostly complete eyebrow regrowth with terminal hair in the affected area(s)&#xD;
Full eyebrow hair: Complete eyebrow regrowth with terminal hair in the affected area(s)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject's Eyebrow Assessment</measure>
    <time_frame>Six months</time_frame>
    <description>Determination of the amount of hair in the affected area.&#xD;
Subject's Eyebrow Assessment Grade Descriptor 0 No eyebrow hair: No thick, coarse hairs are visible in the affected area(s)&#xD;
A little eyebrow hair: A few thick, coarse hairs are visible in the affected area(s)&#xD;
Some eyebrow hair: Numerous thick, coarse hairs are visible in the affected area(s)&#xD;
Most eyebrow hair: The majority of the affected area(s) of the eyebrow is covered in thick, coarse hairs&#xD;
Full eyebrow hair: The affected area(s) of the eyebrow is fully covered in thick, coarse hairs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Alopecia Areata</condition>
  <condition>Alopecia Totalis</condition>
  <condition>Alopecia Universalis</condition>
  <arm_group>
    <arm_group_label>ATI-50002 Topical Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATI-50002 Topical Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATI-50002</intervention_name>
    <description>Topical Solution</description>
    <arm_group_label>ATI-50002 Topical Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is at least 18 years of age.&#xD;
&#xD;
          2. Subject has, based on a subject history and clinical examination, a clinical diagnosis&#xD;
             of AA, AU or AT with no eyebrow hair in the affected area(s) and no eyebrow regrowth&#xD;
             over the previous 6 months. Affected area is defined as the area(s) of eyebrow hair&#xD;
             loss identified at Baseline.&#xD;
&#xD;
          3. Subject has a Clinician Eyebrow Assessment score of 0 for at least one eyebrow.&#xD;
&#xD;
          4. Subject has a Subject Eyebrow Assessment score of 0 for at least one eyebrow.&#xD;
&#xD;
          5. Subject has a duration of the current episode of AA, AU or AT with unilateral or&#xD;
             bilateral loss of eyebrow hairs (with at least one distinct patch of &gt;30% loss of&#xD;
             eyebrow hair) for at least 6 months and no more than seven years prior to Visit 1.&#xD;
&#xD;
          6. Subjects who are Women of Childbearing Potential (WOCBP) must have a negative serum&#xD;
             pregnancy test at Screening and a negative urine pregnancy test at Baseline and agree&#xD;
             to use a highly effective method of birth control for the duration of the study and&#xD;
             for 30 days after last study medication application.&#xD;
&#xD;
          7. Subject is non-pregnant and non-lactating and not planning a pregnancy during the&#xD;
             duration of the study and for 30 days after the last study medication application.&#xD;
&#xD;
          8. Subject is in good general health and free of any known disease state or physical&#xD;
             condition which, in the opinion of the investigator, would interfere with the study&#xD;
             requirements or put the subject at undue risk by study participation.&#xD;
&#xD;
          9. Subject is willing and able to follow all study instructions and to attend all study&#xD;
             visits.&#xD;
&#xD;
         10. Subjects taking hormonal replacement therapy must have been on the same dose for at&#xD;
             least 6 months prior to Visit 1 and must agree to maintain the same dose for the&#xD;
             duration of the study and for 90 days after the last study medication application.&#xD;
&#xD;
         11. Subjects taking thyroid replacement therapy must have been on the same dose for at&#xD;
             least 6 months prior to Visit 1 and must agree to maintain the same dose for the&#xD;
             duration of the study.&#xD;
&#xD;
         12. Subject agrees to refrain from any eyebrow removal (e.g.Â¸ plucking, threading, etc.)&#xD;
             for the duration of the study.&#xD;
&#xD;
         13. Subject agrees to refrain from any cosmetic surgery (e.g., piercing, tattooing, etc.),&#xD;
             on the treatment areas, for the duration of the study.&#xD;
&#xD;
         14. Subject can comprehend and is willing to sign an Informed Consent Form (ICF).&#xD;
&#xD;
         15. Sexually active male subjects must agree to use a barrier method of contraception from&#xD;
             the first application of study medication to at least 30 days after the last&#xD;
             application of study medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has, in the opinion of the investigator, permanent eyebrow loss attributed to&#xD;
             causes other than AA, AU or AT such as overgrooming, or scarring hair loss.&#xD;
&#xD;
          2. Subject currently has, or has a history of, skin disease in the eyebrow area (e.g.,&#xD;
             psoriasis, seborrheic dermatitis, etc.) that, in the opinion of the investigator,&#xD;
             would interfere with the study medication application or study assessments.&#xD;
&#xD;
          3. Subject currently has, or has a history of, severe, progressive or uncontrolled&#xD;
             autoimmune, metabolic, endocrinologic, renal, hepatic, gastrointestinal, pulmonary,&#xD;
             cardiovascular, genitourinary (i.e., renal disease), hematological disease, neurologic&#xD;
             or cerebral disorders, infectious disease or coagulation disorders that, in the&#xD;
             opinion of the investigator, put the subject at undue risk by study participation.&#xD;
&#xD;
          4. Subject currently has, or has a history of, proven or suspected systemic or cutaneous&#xD;
             malignancy and /or lymphoproliferative disease, other than a history of adequately&#xD;
             treated, well healed and completely cleared non-melanoma skin cancers (e.g. basal or&#xD;
             squamous cell carcinoma) treated successfully at least one year prior to Visit 1.&#xD;
&#xD;
          5. Subject currently has evidence of active or latent bacterial infection, including&#xD;
             tuberculosis, or viral infections at the time of enrollment or a history of&#xD;
             incompletely treated or untreated tuberculosis. Subjects who have completed therapy&#xD;
             for latent tuberculosis may participate.&#xD;
&#xD;
          6. Subject has a history of serious local infection (e.g., cellulitis, abscess) or a&#xD;
             systemic infection, including but not limited to, pneumonia or septicemia, within 12&#xD;
             weeks prior to Visit 1. Subjects on an antibiotic for a nonserious, acute local&#xD;
             infection must complete the antibiotic course prior to enrollment in the study.&#xD;
&#xD;
          7. Subjects positive for HIV, Hepatitis B or C.&#xD;
&#xD;
          8. Subject currently has or has a known history of herpes zoster or cytomegalovirus (CMV)&#xD;
             within 8 weeks prior to Visit 1.&#xD;
&#xD;
          9. Subject has a history of frequent outbreaks of Herpes Simplex Virus defined as 4 or&#xD;
             more episodes per year.&#xD;
&#xD;
         10. Subject has any history of eyebrow tattooing, or microblading that in the opinion of&#xD;
             the investigator would interfere with the assessment of safety or efficacy.&#xD;
&#xD;
         11. Subject has used any semi-permanent eyebrow coloring (e.g., tinting, dying, etc.)&#xD;
             within 6 months prior to Visit 1 that in the opinion of the investigator would&#xD;
             interfere with the assessment of safety or efficacy.&#xD;
&#xD;
         12. Clinically significant laboratory abnormalities at Screening that, in the opinion of&#xD;
             the Investigator, would make the subject a poor candidate for the study.&#xD;
&#xD;
         13. Subjects with absolute neutrophil count &lt;1,000/mm3, or platelet count &lt;50,000/ml.&#xD;
&#xD;
         14. Subject used any of the following therapies within the specified period prior to Visit&#xD;
             1:&#xD;
&#xD;
             Systemic therapies:&#xD;
&#xD;
               -  Disease Modifying Anti-Rheumatic Drugs (DMARDS), Biologics or immunosuppressants,&#xD;
                  such as: anakinra, adalimumab, azathioprine, glucocorticosteroids, cyclosporine,&#xD;
                  etanercept, infliximab, methotrexate, TNF inhibitors, ustekinumab, secukinumab,&#xD;
                  ixekizumab, certolizumab pegol: 4 weeks or 5 half-lives whichever is longer&#xD;
&#xD;
               -  Oral retinoids: 12 weeks&#xD;
&#xD;
               -  Plaquenil: 8 weeks&#xD;
&#xD;
               -  JAK inhibitors (oral or topical): 1 year&#xD;
&#xD;
               -  Intralesional steroids on the eyebrow area: 4 weeks&#xD;
&#xD;
             Topical therapies on the eyebrow area:&#xD;
&#xD;
               -  Phototherapy, Laser Therapy : 12 weeks&#xD;
&#xD;
               -  Anthralin, bimatoprost, glucocorticosteroids, diphencyprone,&#xD;
                  diphenylcycloprophenone (DPCP), Squaric acid dibutyl ester (SADBE), minoxidil,&#xD;
                  pimecrolimus, tacrolimus: 4 weeks&#xD;
&#xD;
               -  Topical treatments (prescription and over-the-counter) that contain retinoids,&#xD;
                  retinol, alpha hydroxy acids (e.g. glycolic, lactic acids) and beta hydroxy acids&#xD;
                  (e.g. salicylic acid) on and around the eyebrow area: 4 weeks&#xD;
&#xD;
         15. Subject has a history of sensitivity to any of the ingredients in the study&#xD;
             medication.&#xD;
&#xD;
         16. Subject has participated in an investigational drug or device trial in which&#xD;
             administration of an investigational study drug or device occurred within 30 days or 5&#xD;
             half-lives (whichever is longer) prior to Visit 1. Subjects who have participated in a&#xD;
             study of an investigational drug, device or biologic agent for alopecia areata (AA, AU&#xD;
             or AT) within 1 year of screening will be eligible to participate only with individual&#xD;
             permission from the Medical Monitor.&#xD;
&#xD;
         17. History of or current alcohol or drug abuse within 2 years of assessment for study&#xD;
             enrollment.&#xD;
&#xD;
         18. Screening ECG findings of:&#xD;
&#xD;
               -  QTcF &gt;450msec for males or &gt;470msec for females (use of the ECG algorithm is&#xD;
                  acceptable for this purpose)&#xD;
&#xD;
               -  Heart rate &lt; 45 or &gt; 100 beats/minutes (inclusive)&#xD;
&#xD;
               -  Rhythm disturbance other than sinus arrhythmia or ectopic supraventricular rhythm&#xD;
                  (ectopic atrial rhythm)&#xD;
&#xD;
               -  Conduction disturbance including PR &gt;240msec, pre-excitation (delta wave and PR&#xD;
                  &lt;120msec), second degree or higher AV block&#xD;
&#xD;
               -  Acute or chronic signs of ischemia&#xD;
&#xD;
               -  Left Bundle Branch Block&#xD;
&#xD;
               -  Prior myocardial infarction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aclaris Investigator Site</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2018</study_first_posted>
  <results_first_submitted>October 30, 2019</results_first_submitted>
  <results_first_submitted_qc>November 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2019</results_first_posted>
  <last_update_submitted>November 21, 2019</last_update_submitted>
  <last_update_submitted_qc>November 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT03551821/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ATI-50002 Topical Solution</title>
          <description>ATI-50002 Topical Solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ATI-50002 Topical Solution</title>
          <description>ATI-50002 Topical Solution&#xD;
ATI-50002: Topical Solution</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="50" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinician's Eyebrow Assessment</title>
        <description>Determination of the amount of hair in the affected area.&#xD;
Clinician's Eyebrow Assessment&#xD;
Grade Descriptor 0 No eyebrow hair: No terminal hairs are visible in the affected area(s)&#xD;
A little eyebrow hair: Occasional terminal hairs are visible in the affected area(s)&#xD;
Some eyebrow hair: Numerous terminal hairs are visible in the affected area(s)&#xD;
Most eyebrow hair: Mostly complete eyebrow regrowth with terminal hair in the affected area(s)&#xD;
Full eyebrow hair: Complete eyebrow regrowth with terminal hair in the affected area(s)</description>
        <time_frame>Six months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ATI-50002 Topical Solution</title>
            <description>ATI-50002 Topical Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician's Eyebrow Assessment</title>
          <description>Determination of the amount of hair in the affected area.&#xD;
Clinician's Eyebrow Assessment&#xD;
Grade Descriptor 0 No eyebrow hair: No terminal hairs are visible in the affected area(s)&#xD;
A little eyebrow hair: Occasional terminal hairs are visible in the affected area(s)&#xD;
Some eyebrow hair: Numerous terminal hairs are visible in the affected area(s)&#xD;
Most eyebrow hair: Mostly complete eyebrow regrowth with terminal hair in the affected area(s)&#xD;
Full eyebrow hair: Complete eyebrow regrowth with terminal hair in the affected area(s)</description>
          <units>score on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject's Eyebrow Assessment</title>
        <description>Determination of the amount of hair in the affected area.&#xD;
Subject's Eyebrow Assessment Grade Descriptor 0 No eyebrow hair: No thick, coarse hairs are visible in the affected area(s)&#xD;
A little eyebrow hair: A few thick, coarse hairs are visible in the affected area(s)&#xD;
Some eyebrow hair: Numerous thick, coarse hairs are visible in the affected area(s)&#xD;
Most eyebrow hair: The majority of the affected area(s) of the eyebrow is covered in thick, coarse hairs&#xD;
Full eyebrow hair: The affected area(s) of the eyebrow is fully covered in thick, coarse hairs</description>
        <time_frame>Six months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ATI-50002 Topical Solution</title>
            <description>ATI-50002 Topical Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Eyebrow Assessment</title>
          <description>Determination of the amount of hair in the affected area.&#xD;
Subject's Eyebrow Assessment Grade Descriptor 0 No eyebrow hair: No thick, coarse hairs are visible in the affected area(s)&#xD;
A little eyebrow hair: A few thick, coarse hairs are visible in the affected area(s)&#xD;
Some eyebrow hair: Numerous thick, coarse hairs are visible in the affected area(s)&#xD;
Most eyebrow hair: The majority of the affected area(s) of the eyebrow is covered in thick, coarse hairs&#xD;
Full eyebrow hair: The affected area(s) of the eyebrow is fully covered in thick, coarse hairs</description>
          <units>score on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ATI-50002 Topical Solution</title>
          <description>ATI-50002 Topical Solution</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Executive Director Clinical Operations</name_or_title>
      <organization>Aclaris Therapeutics</organization>
      <phone>4843247933</phone>
      <email>jschnyder@aclaristx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

